About Ruth Roberts

Professor Ruth A Roberts, PhD, ATS, FBTS, ERT, FRSB, FRCPath Director and Cofounder, ApconiX, UK and Chair and Director of Drug Discovery, University of Birmingham, UK Ruth is chair of drug discovery at Birmingham University, UK and Cofounder of ApconiX, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Previously, Ruth was Global Head of Regulatory Safety at AstraZeneca and Director of Toxicology for Aventis. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development. With >140 publications in peer reviewed journals, she is focused on reducing attrition attributable to safety and toxicity. A former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT and president elect of the Academy of Toxicological Sciences, Ruth was the recipient of the SOT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009 and the SOT Founders award in 2018 for outstanding leadership in toxicology.

Understanding drug targets: no such thing as bad news

Abstract: How can small-to-medium pharma and biotech companies enhance the chances of running a successful drug project and maximise the return on a limited number of assets? Having a full appreciation of the safety risks associated with proposed drug targets is a crucial element in understanding the unwanted side-effects that might stop a project in [...]

By | 2018-06-13T16:08:37+00:00 June 6th, 2018|Toxicology, Publications|Comments Off on Understanding drug targets: no such thing as bad news

Ruth wins the 2018 SOT Founders Award!

The official photographs are out to show that it was all smiles in San Antonio earlier this year when I received the 2018 Society of Toxicology (SOT) founders award.  I was proud to be presented with the  plaque by my good friend and colleague, Leigh Ann Burns Naas.  Dr Burns Naas is SOT President as [...]

By | 2018-05-30T13:46:49+00:00 May 24th, 2018|Events|Comments Off on Ruth wins the 2018 SOT Founders Award!

Safety Must Be Prioritized In Drugs for Cancer

Despite the fact that the number of diagnosed cases of malignant mesothelioma are expected to rise in the next decades, there has been little real progress in available treatments, and the chemotherapy drug used to treat the disease is the same one that has been used for the last several  years. Though there is a [...]

By | 2018-05-23T16:46:08+00:00 May 16th, 2018|Press|Comments Off on Safety Must Be Prioritized In Drugs for Cancer

RSB Presidents Dinner

Ruth Roberts (ApconiX) and Emma Walker (Kings College London) attended the Royal Society of Biology President's Dinner May 2nd 2018 where they chatted with Stephen Benn about the great work he does as Vice-President of the Parliamentary and Scientific Committee and for the Society as their Director of Parliamentary Affairs. Professor Dame Julia Goodfellow succeeded [...]

By | 2018-05-30T14:40:15+00:00 May 9th, 2018|Events|Comments Off on RSB Presidents Dinner

ApconiX @ The BTS Congress 2018!

We were delighted to sponsor the poster and drinks reception at the annual British Toxicology Society meeting April 2018. The posters were fascinating with lots of new data on topics such as differentiated pluripotent stem cells, predicting and avoiding drug-induced toxicity and characterisation of cardiac stem cells for assessment of cardiotoxicity.  There were also some [...]

By | 2018-05-23T16:40:25+00:00 April 18th, 2018|Events|Comments Off on ApconiX @ The BTS Congress 2018!

Xenogesis & Sygnature Hosted Meeting

ApconiX enjoyed a double-billing at the recent ‘Predictive Toxicology in Discovery DMPK’ meeting hosted by Sygnature Discovery and Xenogesis in Nottingham.  Ruth Roberts kicked off the event with the keynote address entitled ‘Roberts Derisking early drug projects Shortened Version March 2018’ (click the title for pdf).  Mike Morton addressed the conference later on in the [...]

By | 2018-06-06T15:26:57+00:00 March 23rd, 2018|Events|Comments Off on Xenogesis & Sygnature Hosted Meeting

Post SOT ApconiX Post!

Team ApconiX (Ruth Roberts, Richard Knight, Mike Morton, Paul Duffy and Claire Sadler) had a truly outstanding SOT2018 with great new science and great new contacts.  Ruth Roberts was the proud recipient of the 2018 SOT Founders Award presented by SOT president Patti Ganey.  Claire Sadler presented in a session on Elevator Pitch followed by [...]

By | 2018-06-13T09:12:34+00:00 March 19th, 2018|Events|Comments Off on Post SOT ApconiX Post!

Team ApconiX will be @ SOT2018!

Ruth Roberts, Richard Knight, Mike Morton, Paul Duffy and Claire Sadler will be at SOT2018.  We’d love to talk to you about how ApconiX can add value to your projects through better decisions in project toxicology, target safety assessments and ion channel/hERG screening.  Every project is unique and needs the guidance of experts to ensure [...]

By | 2018-06-06T14:46:29+00:00 March 8th, 2018|Events|Comments Off on Team ApconiX will be @ SOT2018!

Changes in the metabolome and microRNA levels in biological fluids might represent biomarkers of neurotoxicity: A trimethyltin study.

Abstract: Neurotoxicity has been linked with exposure to a number of common drugs and chemicals, yet efficient, accurate, and minimally invasive methods to detect it are lacking. Fluid-based biomarkers such as those found in serum, plasma, urine, and cerebrospinal fluid have great potential due to the relative ease of sampling but at present, data on [...]

By | 2018-06-13T16:07:16+00:00 February 28th, 2018|Toxicology, Publications|Comments Off on Changes in the metabolome and microRNA levels in biological fluids might represent biomarkers of neurotoxicity: A trimethyltin study.

The Value of Target Safety Assessments

Did you know that safety issues remain one of the main reason why drug projects fail?   Multiple publications over recent years have continued to highlight non-clinical safety/toxicity as the most frequent reason for project failure in drug development.  For example, in a study of 605 projects from GSK, AstraZeneca, Ely Lilly and Pfizer, nonclinical toxicology [...]

By | 2018-06-13T15:59:10+00:00 February 28th, 2018|Target Safety Assessments|Comments Off on The Value of Target Safety Assessments